InnoSkel

InnoSkel is a biotechnology firm focused on the development of innovative therapies for collagen-related disorders, emphasizing research and technology to create impactful medical solutions. InnoSkel is engaged in biotechnology, specifically targeting type 2 collagenopathies with its main program. Founded in 2020 in France, the company has raised a total of EUR 19. 4 mn, with its latest funding round, Series A, completed on January 20, 2021.

This round was co-led by Jeito Capital and Vida Ventures, with participation from Région Sud Investissement and Turenne Groupe. Elvire Gouze serves as both the CEO and founder of the company, which has undergone transitions to focus its operations on developing drug candidates and enhancing its management team. InnoSkel is focused on developing innovative therapies aimed at treating type 2 collagenopathies. The company’s offerings are based on advanced research aimed at addressing significant unmet medical needs in collagen-related disorders, demonstrating a commitment to scientific rigor and impactful healthcare solutions.

InnoSkel has structured its financial model around strategic funding, with a focus on project-specific milestones to ensure effective utilization of resources. Revenue generation is primarily through securing investments designed to support research and development efforts, particularly as they advance toward clinical trials. InnoSkel plans to utilize its recent funding of EUR 19. 4 mn, raised during the Series A round, to achieve specific milestones in its research and development program.

Upcoming initiatives include the selection of a lead drug candidate targeted for type 2 collagenopathies and the recruitment of a Chief Medical Officer. Additionally, the company aims to transition its laboratory operations from Inserm to its own premises and ensure full dedication from its CEO, Elvire Gouze, to the firm. These steps are expected to enhance InnoSkel's operational capabilities and advance its growth trajectory in the biotechnology sector.